tradingkey.logo

ARS Pharmaceuticals Inc

SPRY
10.030USD
+0.360+3.72%
終値 02/06, 16:00ET15分遅れの株価
991.41M時価総額
損失額直近12ヶ月PER

ARS Pharmaceuticals Inc

10.030
+0.360+3.72%

詳細情報 ARS Pharmaceuticals Inc 企業名

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

ARS Pharmaceuticals Incの企業情報

企業コードSPRY
会社名ARS Pharmaceuticals Inc
上場日Dec 04, 2020
最高経営責任者「CEO」Lowenthal (Richard E)
従業員数155
証券種類Ordinary Share
決算期末Dec 04
本社所在地11682 El Camino Real, Suite 300
都市SAN DIEGO
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号92130
電話番号18587719307
ウェブサイトhttps://ars-pharma.com/
企業コードSPRY
上場日Dec 04, 2020
最高経営責任者「CEO」Lowenthal (Richard E)

ARS Pharmaceuticals Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.83M
-1143342.00%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
4.57M
-556658.00%
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-2969.00%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--
Dr. Peter A. Thompson, M.D.
Dr. Peter A. Thompson, M.D.
Independent Director
Independent Director
--
--
Mr. Saqib Islam, J.D.
Mr. Saqib Islam, J.D.
Independent Director
Independent Director
--
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Eric Karas
Mr. Eric Karas
Chief Commercial Officer
Chief Commercial Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.83M
-1143342.00%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
4.57M
-556658.00%
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-2969.00%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--

収益内訳

会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。

株主

更新時刻: Sat, Jan 31
更新時刻: Sat, Jan 31
株主統計
種類
株主統計
株主統計
比率
RA Capital Management, LP
10.99%
OrbiMed Advisors, LLC
8.39%
Deerfield Management Company, L.P.
7.59%
Lowenthal (Richard E)
6.91%
Pratik Shah Living Trust
4.88%
他の
61.25%
株主統計
株主統計
比率
RA Capital Management, LP
10.99%
OrbiMed Advisors, LLC
8.39%
Deerfield Management Company, L.P.
7.59%
Lowenthal (Richard E)
6.91%
Pratik Shah Living Trust
4.88%
他の
61.25%
種類
株主統計
比率
Hedge Fund
22.26%
Investment Advisor/Hedge Fund
20.07%
Investment Advisor
18.32%
Venture Capital
15.19%
Individual Investor
11.94%
Private Equity
8.39%
Corporation
4.88%
Research Firm
3.80%
Insurance Company
0.59%

機関投資家保有株

更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
396
88.46M
89.49%
-9.70M
2025Q3
381
87.74M
88.78%
-2.41M
2025Q2
367
96.00M
97.76%
-11.66M
2025Q1
380
100.63M
102.48%
-12.75M
2024Q4
345
96.62M
99.42%
-14.07M
2024Q3
320
88.19M
90.90%
-18.52M
2024Q2
291
87.17M
89.94%
-20.35M
2024Q1
289
89.45M
92.60%
-16.44M
2023Q4
280
92.18M
96.08%
-6.49M
2023Q3
283
95.82M
104.35%
+1.21M
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
RA Capital Management, LP
10.86M
10.99%
--
--
Sep 30, 2025
OrbiMed Advisors, LLC
8.29M
8.39%
--
--
Sep 30, 2025
Deerfield Management Company, L.P.
7.50M
7.59%
-106.41K
-1.40%
Sep 30, 2025
Lowenthal (Richard E)
6.83M
6.91%
-1.14M
-14.34%
Mar 31, 2025
Pratik Shah Living Trust
4.82M
4.88%
--
--
Mar 31, 2025
Tanimoto (Sarina)
4.57M
4.63%
-556.66K
-10.85%
Mar 31, 2025
Rubric Capital Management LP
4.50M
4.55%
+3.21M
+247.52%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.35M
4.4%
+419.68K
+10.68%
Sep 30, 2025
SR One Capital Management, LP
4.01M
4.06%
--
--
Sep 30, 2025
abrdn Inc.
3.10M
3.13%
+1.59M
+106.11%
Sep 30, 2025
詳細を見る

関連ETF

更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
ALPS Medical Breakthroughs ETF
0.38%
State Street SPDR S&P Biotech ETF
0.32%
Direxion Daily S&P Biotech Bull 3X Shares
0.16%
VictoryShares US Small Mid Cap Value Momentum ETF
0.16%
ProShares Ultra Nasdaq Biotechnology
0.11%
Principal U.S. Small-Cap ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares US Small-Cap Equity Factor ETF
0.05%
iShares Biotechnology ETF
0.05%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.04%
詳細を見る
ALPS Medical Breakthroughs ETF
比率0.38%
State Street SPDR S&P Biotech ETF
比率0.32%
Direxion Daily S&P Biotech Bull 3X Shares
比率0.16%
VictoryShares US Small Mid Cap Value Momentum ETF
比率0.16%
ProShares Ultra Nasdaq Biotechnology
比率0.11%
Principal U.S. Small-Cap ETF
比率0.09%
Invesco Nasdaq Biotechnology ETF
比率0.08%
iShares US Small-Cap Equity Factor ETF
比率0.05%
iShares Biotechnology ETF
比率0.05%
iShares MSCI USA Small-Cap Min Vol Factor ETF
比率0.04%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
KeyAI